SecBot SecBot

HALO drug pipeline

$96.50
−3.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.3%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
7
7 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since 2020, with multiple FDA-approved indications. No additional regulatory milestones are pending for this specific product.

DARZALEX Faspro daratumumab and hyaluronidase-fihj Updated Nov 8

What to watch

DARZALEX Faspro is an already-approved, commercially mature product with no upcoming binary catalyst for Halozyme. The next stock-moving events for Halozyme are quarterly royalty reports and the Merck Keytruda Qlex patent litigation outcome. Investors should watch J&J's quarterly daratumumab sales figures and Halozyme's Q4 2026 earnings for royalty growth trajectory.

Bull case
  • DARZALEX Faspro generated $4.239 billion in global net sales in Q3 2026 alone, a massive and growing revenue stream that generates substantial ENHANZE royalties for Halozyme.
  • Halozyme's Q3 2026 ENHANZE royalty revenue jumped 44% YoY to a record $341 million, with DARZALEX Faspro being a major contributor.
  • Multiple recent FDA approvals (smoldering myeloma Nov 2025, NDMM quadruplet Jan 2026, TECVAYLI combo Mar 2026) continue to expand the addressable market.
Bear case
  • DARZALEX Faspro is a mature marketed product; no binary catalysts remain for Halozyme shareholders tied to this drug.
  • Halozyme's ENHANZE royalty stream depends on partner product sales, which could face pricing pressure or competition from oral/next-gen therapies.
  • The recent 15.7% stock drop (Nov 6) despite a Q3 beat reflects concerns about marginal guidance raise and a Leerink downgrade to Market Perform.
● neutral
Impact
PhaseApproved (platform technology; individual partnered products have their own regulatory status)
Time to marketAlready approved and commercialized via multiple partnered products. Ongoing expansion through new partnership deals.

ENHANZE Updated Oct 24

What to watch

HALO's ENHANZE platform generates recurring royalty revenue from several approved partnered products. Watch for new ENHANZE collaboration deals (which can be catalysts) and Q3 2026 earnings on Nov 5, 2026 for the latest financials. The stock is near its 52-week high (~$126) with an overbought RSI of ~74, suggesting near-term caution, but the underlying business benefits from a growing roster of partnered subcutaneous biologics.

Bull case
  • ENHANZE is an already-approved, de-risked technology platform generating recurring royalty revenues from multiple partnered products (Roche's Phesgo, Herceptin Hylecta; J&J's Darzalex Faspro; argenx's Vyvgart Hytrulo), with no binary FDA risk for the platform itself.
  • The analyst consensus is strongly positive: 13 Buy/Strong Buy, 3 Hold, 0 Sell as of October 2026. HC Wainwright, TD Cowen, and JMP Securities rate it Buy. Leerink Partners upgraded to Outperform in August 2026.
  • HALO has strong price momentum: up ~50.6% over 3 months and ~94.8% over 6 months. The stock is well above its SMA200 of ~$81.94 (+53%). The ADX-14 of ~30.7 indicates a strong bullish trend.
Bear case
  • ENHANZE is not a proprietary drug, it's an enabling technology platform, so Halozyme's revenue depends on partner success and royalty rates, not its own pricing power.
  • CEO Helen Torley executed several large stock sales in October 2026 (~$3M+ total) under a 10b5-1 plan, which could signal limited near-term upside conviction at current (near-52-week-high) levels.
  • Short interest as % of shares outstanding was ~13.48% as of Sept 30, 2026 settlement date, reflecting elevated bearish positioning. FINRA short-volume ratio has frequently been elevated (above 60%) in recent months.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since June 2020 (FDA) and December 2020 (EU).

Phesgo pertuzumab/trastuzumab/hyaluronidase-zzxf Updated Nov 8

What to watch

Phesgo is a mature, approved product with no pending FDA decision. Watch Halozyme's quarterly royalty revenue reports for Phesgo's commercial trajectory, and monitor Roche's quarterly sales disclosures for Phesgo growth trends. Any label expansion or new indication for Phesgo would be a positive catalyst for Halozyme's royalty stream.

Bull case
  • Phesgo is a blockbuster product that generated strong sales growth for Roche, contributing to Halozyme's record Q3 2026 royalty revenue of $341 million (up 44% YoY).
  • Phesgo offers faster subcutaneous administration (minutes vs hours for IV), and 85% of patients preferred it over IV in trials, driving adoption.
  • Halozyme raised its full-year 2026 guidance after Q3, reflecting confidence in continued royalty growth from Phesgo and other ENHANZE-partnered products.
Bear case
  • Phesgo is a Roche drug, not a Halozyme drug; Halozyme only earns a royalty on sales, limiting its upside exposure.
  • HALO stock dropped ~15.7% on Nov 6, 2026 despite a Q3 earnings beat and raised guidance, reflecting a Leerink downgrade and concerns that growth is already priced in.
  • CEO Helen Torley sold shares worth ~$1.3M in October 2026 under a 10b5-1 plan, and other insiders also sold, signaling limited near-term upside conviction.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since September 2024.

TECENTRIQ HYBREZA atezolizumab and hyaluronidase-tqjs Updated Nov 8

What to watch

Tecentriq Hybreza is already approved and generating royalties for Halozyme. Watch for future label expansions by Roche/Genentech that could incrementally boost royalty revenue, and for Halozyme's quarterly royalty reports to track commercial uptake. The next catalyst for HALO as a whole is more likely to be partnership deals, patent litigation outcomes (e.g., the Merck Keytruda Qlex dispute), or quarterly earnings rather than a specific Tecentriq Hybreza event.

Bull case
  • Tecentriq Hybreza is the first and only FDA-approved subcutaneous anti-PD-(L)1 immunotherapy, offering a competitive advantage in patient convenience (7-minute injection vs 30-60 min IV infusion).
  • The drug covers all adult indications of IV Tecentriq, which spans 12 approved cancer types, providing a large addressable market.
  • Halozyme's ENHANZE royalty revenue grew 44% YoY to $341M in Q3 2026, with Tecentriq Hybreza as a contributor alongside other partnered products.
Bear case
  • Tecentriq Hybreza is developed and marketed by Roche/Genentech, not Halozyme. Halozyme only earns royalties, limiting its upside compared to owning the drug outright.
  • Competition from Merck's Keytruda (pembrolizumab) is intense in the PD-(L)1 space, and Merck is developing a subcutaneous version (Keytruda Qlex) using its own technology, which could pressure Tecentriq Hybreza's market share.
  • Leerink Partners downgraded HALO to Market Perform from Outperform on November 7, 2026, citing only 'marginal' Q3 upside.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA-approved since 2019)

XYOSTED testosterone enanthate Updated Oct 24

What to watch

XYOSTED itself presents no near-term binary catalyst. For HALO investors, the focus should be on ENHANZE royalty revenue growth (driven by partners like argenx's VYVGART Hytrulo and J&J's DARZALEX FASPRO) and the Q3 2026 earnings report on November 5, 2026. The stock trades above its mean analyst target, suggesting limited near-term upside based on consensus estimates.

Bull case
  • Steady commercial revenue from an established, FDA-approved product with a clear use case (testosterone replacement) and a convenient auto-injector delivery format.
  • Part of a diversified product portfolio at Halozyme that includes higher-growth ENHANZE-royalty assets, providing revenue stability.
  • Acquired at a reasonable valuation ($960M for Antares Pharma including XYOSTED and other assets), and adds to Halozyme's self-injection device capabilities.
Bear case
  • Competition in the testosterone replacement market is intense, AbbVie's AndroGel, Endo's Aveed, and various generic/other topical and injectable testosterone products limit XYOSTED's market share and pricing power.
  • As a relatively small product within Halozyme's portfolio, XYOSTED's performance has limited impact on HALO stock price.
  • Testosterone replacement therapy faces ongoing regulatory scrutiny regarding cardiovascular safety and appropriate prescribing practices, which could impact the category.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

Aerocon Updated Oct 24

What to watch

The drug "Aerocon" could not be verified as a real asset. If it appeared in a filing as a pipeline candidate, check the original EDGAR document directly for context. For Halozyme (HALO), upcoming catalysts include Q3 2026 earnings on Nov 5, 2026, and continued execution of its partnered ENHANZE royalty stream, but no drug by this name appears in its known pipeline.

Bull case
  • Halozyme (HALO) has a strong institutional base with BlackRock holding >$1B and 242 tracked managers long in Q2 2026.
  • Analyst consensus is Buy/Strong Buy (13 positive, 3 hold, 0 sell), with no downgrade momentum in 30/60 days.
  • Halozyme's ENHANZE platform generates recurring royalties from partnered blockbuster drugs (VYVGART Hytrulo, DARZALEX FASPRO) providing a growing revenue base.
Bear case
  • The drug 'Aerocon' could not be verified as a real Halozyme asset through any database, it may be misspelled, non-existent, or an extremely early-stage program with no public data.
  • Halozyme's price targets (mean $108.78) imply ~13.4% downside from the current $125.63 price, suggesting the stock is above consensus fair value.
  • The company recently issued $1.3B in new convertible notes (1.50% due 2033), adding leverage and potential dilution risk if the stock exceeds the ~$208.39 cap price.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

Hypercon Updated Oct 24

What to watch

No actionable insight can be provided because the drug "Hypercon" cannot be identified. Investors should verify the correct drug name from the source filing. HALO remains a revenue-stage biotech trading at ~$125.63 with strong analyst coverage (10 Buy, 3 Hold, 3 Strong Buy) but a mean price target of $108.78 implying ~13% downside from current levels.

Bull case
  • No bull case can be constructed, the drug was not identifiable in any searched database.
Bear case
  • The drug name 'Hypercon' could not be verified as a real asset. This may be a misspelling, a placeholder name, or a non-existent entity in Halozyme's pipeline.

Other drugs in filings and trials

no drug report yet
  • VYVGART Hytrulo Last: Approval · May 11, 2026
  • TECVAYLI Last: Approval · Mar 1, 2026
  • BLA761313 Last: Approval · Jun 20, 2023

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
May 11, 2026VYVGART HytruloApproval+10.6%+5.2%
May 1, 2026VYVGART HytruloApproval+1.4%+0.7%
Mar 1, 2026TECVAYLIApproval+0.5%−3.1%
Jan 1, 2026DARZALEX FasproApproval+4.5%+7.2%
Jun 20, 2023BLA761313Approval+3.3%−2.2%